SUBSTANCE AND NON SUBSTANCE RELATED ADDICTION DISORDERS : diagnosis and treatment (1).
Material type:
TextPublication details: [Place of publication not identified] : BENTHAM Science PUBLISHER, 2017.Description: 1 online resourceContent type: - text
- computer
- online resource
- 1681083434
- 9781681083438
- Substance abuse -- Diagnosis
- Substance abuse -- Treatment
- Compulsive behavior
- Compulsive Behavior
- Behavior, Addictive
- Polytoxicomanie -- Traitement
- Comportement compulsif
- addiction
- HEALTH & FITNESS -- Diseases -- General
- MEDICAL -- Clinical Medicine
- MEDICAL -- Diseases
- MEDICAL -- Evidence-Based Medicine
- MEDICAL -- Internal Medicine
- Compulsive behavior
- Substance abuse -- Diagnosis
- Substance abuse -- Treatment
- 616.86 23
- RC564 .S83 2017
| Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|---|
Electronic-Books
|
OPJGU Sonepat- Campus | E-Books EBSCO | Available |
Includes bibliographical references and index.
FOREWORD ; PREFACE ; List of Contributors ; Section I: General Topics ; Neurobiology and Psycho-Social Basis for Addiction and Related Disorders ; KEY LEARNING POINTS; NEUROBIOLOGY OF ADDICTION AND REWARD PATHWAYS; PSYCHOSOCIAL FACTORS; ADVERSE CHILDHOOD EXPERIENCES (ACE); CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Urine Drug Screening (UDS) in the Management of Substance Use Disorders ; KEY LEARNING POINTS; CLINICAL VIGNETTE; DIAGNOSTIC CONSIDERATION; REASONS FOR OBTAINING AN UDS; URINE DRUG SCREENS; Types of Urine Drug Tests; Urine Drug Test as a Follow-up Tool.
Urine Sample CollectionChain of Custody; Medication Interfering with UDS; SPECIAL CONSIDERATIONS; Opiate/Opioid Metabolism; Benzodiazepines; Untested Substances; Altered Pharmacokinetic and Pharmacodynamic Parameters; SUMMARY; PATIENT INFORMATION SHEET -- URINE DRUG SCREENS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Genetics of Addiction ; KEY LEARNING POINTS; GENETICS OF ADDICTION; SUMMARY; PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Dual Diagnosis ; KEY LEARNING POINTS; CLINICAL VIGNETTE; BACKGROUND; DIAGNOSTIC CONSIDERATIONS.
TREATMENT CONSIDERATIONSTREATMENT OUTCOMES; SUMMARY; DUAL DIAGNOSIS -- PATIENT INFORMATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Pharmacologic Treatment for Psychiatric Disorders Associated with Substance Use Disorders: An Overview ; KEY LEARNING POINTS; INTRODUCTION; Benzodiazepines (Table 1); Antidepressants; Serotonin Syndrome; Syndrome Presentation; Treatment; SSRI Withdrawal Phenomenon; Atypical/Typical Antipsychotics; Dosing; Monitoring; Additional Monitoring Recommended; Other Side Effects; Extrapyramidal Side Effects (EPSE); Treatment of Early -- EPSE.
Dystonias and PseudoparkinsonismAkathisia; Treatment of Tardive Dyskinesia; Neuroleptic Malignancy Syndrome (NMS); Mood Stabilizers; Anticonvulsants; Management of Insomnia; SUMMARY; PATIENT INFORMATION -- MEDICATIONS FOR SUBSTANCE USE DISORDERS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Motivational Interviewing ; KEY LEARNING POINTS; BACKGROUND; PROCESS; MOTIVATION ENHANCEMENT; THE STAGES OF CHANGE; SUMMARY; MOTIVATIONAL INTERVIEW-PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Section II: Substance-Related Addiction Disorders (Alphabetical).
Alcohol Use Disorders KEY POINTS; CLINICAL VIGNETTE; INTRODUCTION; Epidemiology; Etiology; Diagnosis; Non-Pharmacologic Interventions; Pathophysiology of Alcohol Use Disorders (AUD); PHARMACOTHERAPY FOR ALCOHOL USE DISORDERS (AUD); Management of Outpatient Alcohol Withdrawal; FDA Approved Medications for Alcohol Use Disorder [26]; Disulfiram (Antabuse®) [19, 21, 27]; Naltrexone (Revia® (PO), Vivitrol® (IM)); Acamprosate (Campral®) [21, 28, 30]; Combination Therapy; Non-FDA Approved Pharmacotherapies for AD; SUMMARY; CLINICAL VIGNETTE RESOLUTION; PROVIDER RESOURCES.
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide
There are no comments on this title.